Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
about
Antipsychotic medication for childhood-onset schizophreniaAtypicality of atypical antipsychotics.The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's DiseasePrevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-AnalysisContinuing clozapine treatment with lithium in schizophrenic patients with neutropenia or leukopenia: brief review of literature with case reportsPharmacogenetics and outcome with antipsychotic drugsDrug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Clozapine Monitoring in Clinical Practice: Beyond the Mandatory RequirementTreatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychoticsThe Importance of Patient-Specific Factors for Hepatic Drug Response and ToxicityWhat can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?Off-target effects of psychoactive drugs revealed by genome-wide assays in yeastExploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case studyThe Value of Patient-Centred Registries in Phase IV Drug SurveillanceClozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report.Successful clozapine re-challenge in a patient with three previous episodes of clozapine-associated blood dyscrasia.An initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients.Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial.Unrecognized clozapine-related constipation leading to fatal intra-abdominal sepsis - a case report.Zuclopenthixol-associated neutropenia and thrombocytopenia.Clozapine-induced blood dyscrasias in Saudi Arab patients.The use of atypical antipsychotics in the management of schizophrenia.Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs.Effects of quetiapine and olanzapine in patients with psychosis and violent behavior: a pilot randomized, open-label, comparative studyAntipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity.Atypical antipsychotics in older adults.Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease.Drug treatments for schizophreniaClinical features of schizophrenia with enhanced carbonyl stress.Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles.The pharmacology and toxicology of atypical antipsychotic agents.Morning pseudoneutropenia during clozapine treatment.Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study.Late onset clozapine induced agranulocytosis.Hematological safety of metamizole: retrospective analysis of WHO and Swiss spontaneous safety reports.Pharmacogenomics and schizophrenia: clinical implications.Non-chemotherapy drug-induced agranulocytosis.Second-generation antipsychotic medications and risk of pneumonia in schizophrenia.Treatment of bipolar disorder in older adults.
P2860
Q24243972-8EE9B7A3-8AAA-42B9-AB4F-0C41907BF3F1Q24535908-56E71520-7C2B-4550-A70B-5B172A8A71E6Q26738456-5042D6B8-ECC0-481E-B64C-45B48F5CCFD9Q26748476-491F2ADE-37BA-4772-8FDB-4C4AD73D5165Q26766405-F0192DD7-9CEE-4763-A658-0C5DC598323DQ26852807-44E60170-3ED5-4A07-B1E4-9769C060E08AQ27021464-0C9AE2A6-4EF4-4B51-9944-DCDE0B75532FQ28075904-4FBAC411-CF41-4087-9643-D727868B37F4Q28079065-AE2A7817-6980-4839-BFA9-6686C9A32E27Q28080256-653F1B28-6525-4C9A-BC07-B9DE758C361CQ28083481-758D06CA-E4AF-4999-9695-BEFA6BFDA640Q28473277-CC42E68A-15AF-4D2C-8E0E-A8E4DBCF59E4Q28477582-97B6B986-3678-4783-AB6F-C31545C69E51Q29395899-57103650-2EBC-4AE3-BB40-837F7F8D1A02Q30490810-7AC4660E-E8C6-4A34-B926-01051A6834F3Q30490990-1CBF5911-769B-4FDA-A166-D1694BCC3F74Q30491026-480832D3-4C05-4D09-928B-CB772BABBF5DQ32052243-FE0FF0C2-C763-4EF5-9AD3-88F8D43440F4Q33166261-32430484-9AC4-4F7E-B5D2-D32728CCFE3CQ33332870-D793F17D-7DC3-4A7F-8DCB-57C4E17C4E07Q33415861-AB15E7A6-CA2D-4566-90DA-07BC1C7DAA96Q33540449-A967D6D1-E158-4A13-8C4D-FFD1E6AABA34Q33543117-9DE23E3E-8ADF-4CFC-B76A-6F58B08A7D9FQ33604943-536B4F99-F2ED-4A83-AFFB-9B5785BF256AQ33609527-8C20E497-E690-46D6-938A-4AF5EDE36F3FQ33693812-56609EA7-D0CF-4991-9AF8-7F7DABC74E4DQ33726559-2011EA9A-1CDB-4D1F-BBD4-35E2F947BCDCQ33884378-651EE1B6-D8D0-4CD4-9D01-F34C78D91844Q33940113-CEB6AF7E-64A1-4B60-A14E-35D2DB627216Q34048575-8C4F9B68-7155-470C-8269-BCA0B13FF574Q34138234-8C136E97-4292-4B53-B4A2-F1E2DF97F57FQ34235349-4DC0DA7A-25A0-4721-BBD1-0E446BEAF08BQ34275702-53E397E9-D38D-4855-A173-B4F93588C9ABQ34333212-B407EBEE-FF2D-4FFE-8DF6-1E0F3ED3085DQ34363767-6F192FA8-3604-4962-8D87-E5A83CB393A7Q34448129-E61DD44F-8370-41A5-A8EC-FEC7BDC80F5DQ34575636-6009CA1F-3B7C-4999-A3C2-AE0F920B7F66Q34579237-B87A8A0B-7EAB-49A5-AE25-628F74FF504AQ34635425-6A530081-7902-43DC-ADC0-B67709A7ED6DQ34832733-9507E46D-7B47-4F1F-A1BA-0CFC0879F6E0
P2860
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
description
1993 nî lūn-bûn
@nan
1993 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
@ast
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
@en
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
@nl
type
label
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
@ast
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
@en
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
@nl
prefLabel
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
@ast
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
@en
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
@nl
P2093
P1476
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
@en
P2093
Lieberman JA
Safferman AZ
Schwimmer JL
P304
P356
10.1056/NEJM199307153290303
P407
P577
1993-07-01T00:00:00Z